S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Price, News & Analysis

$10.64
+0.73 (+7.36%)
(As of 02/23/2024 ET)
Today's Range
$9.87
$10.66
50-Day Range
$9.89
$11.59
52-Week Range
$8.20
$18.24
Volume
1.45 million shs
Average Volume
199,746 shs
Market Capitalization
$380.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.33

iTeos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
231.9% Upside
$35.33 Price Target
Short Interest
Bearish
6.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.40) to ($4.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.38 out of 5 stars

Medical Sector

732nd out of 936 stocks

Biological Products, Except Diagnostic Industry

127th out of 149 stocks


ITOS stock logo

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS Stock Price History

ITOS Stock News Headlines

Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
iTeos Therapeutics (NASDAQ: ITOS)
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
iTeos to Participate in Upcoming Investor Conferences
Why ITeos Therapeutics (ITOS) Stock Is Moving Higher
H.C. Wainwright Keeps Their Buy Rating on iTeos Therapeutics (ITOS)
See More Headlines
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/25/2024
Next Earnings (Estimated)
3/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ITOS
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.33
High Stock Price Target
$44.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+231.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$96.65 million
Pretax Margin
-87.36%

Debt

Sales & Book Value

Annual Sales
$267.63 million
Cash Flow
$2.69 per share
Book Value
$18.65 per share

Miscellaneous

Free Float
32,135,000
Market Cap
$380.88 million
Optionable
Optionable
Beta
1.14
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report














ITOS Stock Analysis - Frequently Asked Questions

Should I buy or sell iTeos Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITOS shares.
View ITOS analyst ratings
or view top-rated stocks.

What is iTeos Therapeutics' stock price target for 2024?

3 brokers have issued 1 year price targets for iTeos Therapeutics' stock. Their ITOS share price targets range from $29.00 to $44.00. On average, they expect the company's share price to reach $35.33 in the next year. This suggests a possible upside of 231.9% from the stock's current price.
View analysts price targets for ITOS
or view top-rated stocks among Wall Street analysts.

How have ITOS shares performed in 2024?

iTeos Therapeutics' stock was trading at $10.95 on January 1st, 2024. Since then, ITOS stock has decreased by 2.8% and is now trading at $10.6450.
View the best growth stocks for 2024 here
.

Are investors shorting iTeos Therapeutics?

iTeos Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 1,730,000 shares, an increase of 16.1% from the January 15th total of 1,490,000 shares. Based on an average trading volume of 302,100 shares, the days-to-cover ratio is currently 5.7 days. Approximately 6.1% of the shares of the stock are short sold.
View iTeos Therapeutics' Short Interest
.

When is iTeos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our ITOS earnings forecast
.

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) released its earnings results on Wednesday, November, 10th. The company reported $1.86 EPS for the quarter, missing analysts' consensus estimates of $4.95 by $3.09. The company had revenue of $104.27 million for the quarter, compared to the consensus estimate of $329.75 million. During the same quarter in the previous year, the firm earned ($0.48) earnings per share.

What ETFs hold iTeos Therapeutics' stock?

ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).

When did iTeos Therapeutics IPO?

(ITOS) raised $151 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are iTeos Therapeutics' major shareholders?

iTeos Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.17%), Dimensional Fund Advisors LP (2.16%), Goldman Sachs Group Inc. (2.07%), Barclays PLC (0.87%), Northern Trust Corp (0.72%) and Vontobel Holding Ltd. (0.62%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath.
View institutional ownership trends
.

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITOS) was last updated on 2/25/2024 by MarketBeat.com Staff